NCT00105599

Brief Summary

This study of the FairCare Program (FC) is designed to address end of life (EOL) care delivery issues by reducing barriers to effective EOL care among health care providers, family members, surrogates, and Chronic Heart Failure (CHF) patients using a comprehensive, multi-pronged approach delivered by a care coordinator and supported by an interdisciplinary team.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
140

participants targeted

Target at P75+ for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Completion

Last participant's last visit for all outcomes

September 1, 2004

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

March 15, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 16, 2005

Completed
Last Updated

April 7, 2015

Status Verified

February 1, 2007

First QC Date

March 15, 2005

Last Update Submit

April 6, 2015

Conditions

Terminal CareNeoplasm

Study Arms (1)

Arm 1

OTHER
Behavioral: End of life care coordinationProcedure: FairCare System

Interventions

End of life care coordinationBEHAVIORAL
Arm 1
FairCare SystemPROCEDURE
Arm 1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ejection fraction 35% or less and classification at level 3 or 4 of the New York State Heart Classification System and surrogates of patients meeting this criteria.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Albany VA Medical Center Samuel S. Stratton, Albany, NY

Albany, New York, 12208, United States

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Mollie Shulan, MD

    Albany VA Medical Center Samuel S. Stratton, Albany, NY

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 15, 2005

First Posted

March 16, 2005

Study Completion

September 1, 2004

Last Updated

April 7, 2015

Record last verified: 2007-02

Locations

US(1)